TargED Biopharmaceuticals B.V. is a Netherlands based biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using antibodies fragments (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. Its lead compound, TGD001,  is currently tested in a first in human clinical trial and will be further developed for the treatment of thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition. TargED, a spin-off of the University Medical Center Utrecht, was founded in July 2020. Since then, TargED raised more than €45 million of funding, supporting its growth to become a clinical-stage company.